Lab
B.M.Laboratory,inc.
B.M.Laboratory,inc. was paid $1.15M by Medicaid between Jan 2018 and Dec 2024, across 61 billing codes. Its largest line is 87426, Infectious agent antigen detection, SARS-CoV-2 (COVID-19) — 11% of everything it billed.
33Billing provider infoB.M.LABORATORY,INC.
ISABELA, PR 00662
ISABELA, PR 00662
33aNPI1730365032assigned 01/16/2008
33bProvider typeClinical Medical Laboratory
28Total paid$1.15M
24GClaims100,868
24DCodes billed61
24AFirst – last monthJan 2018 – Dec 2024
Compared with peers
Next to other Clinical Medical Laboratory providers in Puerto Rico
Rank by total paid#102 of 777
Median peer was paid$278K
This provider vs. median4.1×
Peers share this provider's primary NPPES type and state. Size alone says nothing about billing quality: a big agency or a hospital system is expected to sit far above the median.
Box 24A · Dates of service
Paid by month
Paid that monthNov–Dec 2024: claims still arriving when the file was cut, so these months run low for every provider
By year, as a table
| Year | Claims | Paid | |
|---|---|---|---|
| 2018 | 11,982 | $107K | |
| 2019 | 10,336 | $90K | |
| 2020 | 9,788 | $122K | |
| 2021 | 15,340 | $227K | |
| 2022 | 16,114 | $228K | |
| 2023 | 18,349 | $190K | |
| 2024incomplete | 18,959 | $181K |
Box 24 · Service lines
What it billed for
| Code | Service | Share | Claims | Bene. records | Paid |
|---|---|---|---|---|---|
| 87426 | Infectious agent antigen detection, SARS-CoV-2 (COVID-19) | 11% | 2,931 | 2,714 | $127K |
| 84443 | Thyroid stimulating hormone (TSH) | 11% | 7,229 | 6,987 | $126K |
| 80061 | Lipid panel | 9.7% | 8,047 | 7,719 | $111K |
| G2023 | Specimen collection for severe acute respiratory syndrome coronavirus 2 (sars-cov-2) (coronavirus disease [covid-19]), any specimen source | 7.6% | 3,747 | 3,435 | $87K |
| 80053 | Comprehensive metabolic panel | 7.2% | 7,637 | 7,285 | $83K |
| 85027 | 6.2% | 10,725 | 10,185 | $72K | |
| 82306 | Vitamin D; 25 hydroxy, includes fraction(s), if performed | 5.1% | 1,950 | 1,857 | $59K |
| 87635 | Infectious agent detection by nucleic acid; SARS-CoV-2 (COVID-19), amplified probe | 4.5% | 1,019 | 986 | $52K |
| 82274 | 4.2% | 2,916 | 2,821 | $48K | |
| 83036 | Hemoglobin; glycosylated (A1C) | 3.8% | 4,350 | 4,181 | $44K |
| 85007 | 3.3% | 10,725 | 10,184 | $37K | |
| 87389 | Infectious agent antigen detection by immunoassay technique, HIV-1 antigen with HIV-1 and HIV-2 antibodies | 2.9% | 1,338 | 1,289 | $33K |
49 more codes
| 36415 | Collection of venous blood by venipuncture | 2.1% | 7,679 | $24K |
| 81001 | 2.0% | 6,892 | $23K | |
| 87804 | Infectious agent antigen detection by immunoassay; Influenza, each type | 1.7% | 1,630 | $20K |
| 84153 | 1.7% | 1,038 | $20K | |
| 80048 | Basic metabolic panel (calcium, ionized) | 1.5% | 2,029 | $18K |
| 82043 | 1.3% | 2,426 | $15K | |
| 82570 | 1.1% | 2,443 | $13K | |
| 86738 | 1.0% | 742 | $12K | |
| 82607 | <1% | 694 | $11K | |
| 86328 | <1% | 554 | $10K | |
| 84439 | <1% | 1,021 | $10K | |
| 87088 | <1% | 1,164 | $10K | |
| 85025 | Blood count; complete (CBC), automated, and automated differential WBC count | <1% | 1,274 | $9K |
| 87086 | Culture, bacterial; quantitative colony count, urine | <1% | 1,098 | $9K |
| 80074 | <1% | 178 | $9K | |
| 87806 | <1% | 338 | $9K | |
| U0002 | 2019-ncov coronavirus, sars-cov-2/2019-ncov (covid-19), any technique, multiple types or subtypes (includes all targets), non-cdc | <1% | 141 | $7K |
| 81000 | <1% | 2,100 | $6K | |
| 86769 | <1% | 130 | $3K | |
| 86803 | <1% | 205 | $3K | |
| 85651 | <1% | 846 | $3K | |
| 84436 | <1% | 431 | $3K | |
| 87591 | Infectious agent detection by nucleic acid; Neisseria gonorrhoeae, amplified probe | <1% | 72 | $3K |
| 87491 | Infectious agent detection by nucleic acid; Chlamydia trachomatis, amplified probe | <1% | 72 | $3K |
| 84479 | <1% | 366 | $2K | |
| 86317 | <1% | 68 | $1K | |
| 82947 | <1% | 362 | $1K | |
| P9604 | Travel allowance one way in connection with medically necessary laboratory specimen collection drawn from home bound or nursing home bound patient; prorated trip charge | <1% | 76 | $1K |
| 87276 | <1% | 95 | $1K | |
| 86592 | <1% | 281 | $1K | |
| 87275 | <1% | 95 | $1K | |
| U0003 | Infectious agent detection by nucleic acid (dna or rna); severe acute respiratory syndrome coronavirus 2 (sars-cov-2) (coronavirus disease [covid-19]), amplified probe technique, making use of high throughput technologies as described by cms-2020-01-r | <1% | 16 | $1K |
| 86140 | <1% | 158 | $828.64 | |
| 87185 | <1% | 170 | $798.95 | |
| 85730 | <1% | 107 | $666.40 | |
| P9615 | Catheterization for collection of specimen(s) (multiple patients) | <1% | 294 | $481.18 |
| 85610 | <1% | 105 | $427.81 | |
| 87899 | <1% | 28 | $316.93 | |
| 83001 | <1% | 15 | $291.10 | |
| 82950 | <1% | 38 | $190.50 | |
| 87338 | <1% | 12 | $188.04 | |
| 83655 | <1% | 12 | $155.56 | |
| 82042 | <1% | 20 | $113.81 | |
| 82565 | <1% | 12 | $62.33 | |
| 84520 | <1% | 12 | $48.03 | |
| 84156 | <1% | 12 | $48.00 | |
| 99211 | Office or other outpatient visit for the evaluation and management of an established patient, minimal severity | 0% | 632 | $0.00 |
| 87811 | Infectious agent antigen detection by immunoassay; SARS-CoV-2 (COVID-19) | 0% | 57 | $0.00 |
| G0471 | Collection of venous blood by venipuncture or urine sample by catheterization from an individual in a skilled nursing facility (snf) or by a laboratory on behalf of a home health agency (hha) | 0% | 14 | $0.00 |
Claims and beneficiary counts add up across code × month rows, so one patient seen every month counts many times. Rows with fewer than 12 claims are suppressed by HHS, so small lines can be missing.
From NPPES
Who's on the registration
Authorized officialMERCADO MORELL, IDALIZ (PRESIDENT)